Is CONMED (CNMD) overvalued or fairly valued?

MarketChacha shows CONMED's valuation in context — a trailing P/E of about 16.3, a forward P/E of about 8.8, a price-to-book of about 1.2 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does CONMED's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.90×) from reported figures — education, not a rating.

What is CONMED's revenue?

CONMED reported revenue of $1.4B for FY2025, with net profit of $47.1M, per official filings.

What is the share price of CONMED (CNMD)?

CONMED last traded at $41.50 (-0.9% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

CONMED

CNMD · NYSE · Healthcare · United States

$41.50-0.9%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 7:34 PM

Snapshot

TickerCNMD

ExchangeNYSE

SectorHealthcare

IndustryMedical Devices

CountryUnited States

Employees3,900

HeadquartersLargo, United States

Market cap$1.2B

P/E (TTM)16.3

P/B1.2

Volume367.28K

Websitewww.conmed.com

Filings tracked6

About CONMED

CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems and the related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries. It also provides battery-powered, autoclavable, large, and small bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under the Hall surgical brand name. In addition, the company offers general surgery products, such as clinical insufflation systems under the AirSeal brand; smoke removal devices under the Buffalo Filter brand; endomechanical products, including the Anchor1 line of tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors, used in minimally invasive surgeries; and electrosurgical solution comprise monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems, and other accessories. Further, it provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products to treat diseases of dilation, hemostasis, biliary, stricture management, infection prevention, and patient monitoring include ECG electrodes, EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.

Profile as reported by Yahoo Finance.

Who owns it

Insiders0.4%
Institutions99.6%
Public & other0.0%

344 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.16.03%
Earnest Partners LLC8.53%
Vanguard Portfolio Management LLC6.90%
Fuller & Thaler Asset Management Inc.5.45%
Bank of America Corporation4.66%
Dimensional Fund Advisors LP4.63%
Vanguard Capital Management LLC4.60%
State Street Corporation4.60%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

Forensic scorecard

Latest ROE of 4.6% is on the low side — the business earns a modest return on shareholder capital.

Cash conversion1.90×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend5.2% → 3.4%

Margin has held broadly steady over the period — stable profitability.

Return on equity4.6%

Latest ROE of 4.6% is on the low side — the business earns a modest return on shareholder capital.

Growth qualityrev 5% · PAT -15%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $334.9M · EPS 1.03

Est. earnings growth -4.9%

Next fiscal year

Rev $1.4B · EPS 4.72

Est. earnings growth +8.7%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$31.4452-wk range$56.64

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Market cap

$1.2B

Day change

-0.9%

P/E (TTM)

16.3

Fwd P/E

8.8

P/B

1.2

Div yield

1.91%

Beta

0.93

Revenue (FY2025)

$1.4B

Net margin

3.4%

ROE

4.6%

Revenue CAGR (2y)

+5.1%

Profit CAGR (2y)

-14.6%

EPS (FY2025)

1.51

Net profit (FY2025)

$47.1M

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about CNMD

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$1.4B	$47.1M	1.51	3.4%	4.6%
FY2024	$1.3B	$132.4M	4.25	10.1%	13.8%
FY2023	$1.2B	$64.5M	2.04	5.2%	7.7%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2025Q3	$337.9M	$2.9M	0.09	0.8%
2025Q2	$342.3M	$21.4M	0.69	6.3%
2025Q1	$321.3M	$6.0M	0.19	1.9%
2024Q3	$316.7M	$49.0M	1.57	15.5%
2024Q2	$332.1M	$30.0M	0.96	9.0%
2024Q1	$312.3M	$19.7M	0.63	6.3%
2023Q3	$304.6M	$15.8M	0.50	5.2%
2023Q2	$317.7M	$13.7M	0.43	4.3%
2023Q1	$295.5M	$1.8M	0.06	0.6%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC6/17/2026material
8-K — Material agreement, Exhibits
SEC6/4/2026material
8-K — Material agreement, Material financial obligation, Exhibits
SEC6/1/2026material
8-K — Executive/director change, Bylaw/charter change, Shareholder vote results, Exhibits
SEC5/20/2026material
10-Q filing
SEC4/30/2026
8-K — Results of operations, Exhibits
SEC4/29/2026material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.